Cipla

6th April 2017

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

We are forwarding herewith press release titled "Cipla USA enters into collaboration with MEDRx".

Thank you,

Yours faithfully,
For Cipla Limited

Kedar Upadhye
Global Chief Financial Officer

Encl: as above

Press Release

Cipla USA enters into a collaboration with MEDRx

Mumbai, April 6, 2017: Cipla Ltd, a global pharmaceutical company, today announced that its wholly owned subsidiary in USA — Cipla USA Inc. has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine[1] patch for the management of Spasticity.

Under the terms of the agreement, MEDRx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments. MEDRx will also receive tiered royalties on the net sales of commercialized licensed products.

MRX-4TZT is a medicated patch that uses ILTS® (Ionic Liquid Transdermal System), an exclusive MEDRx technology that incorporates its ionic liquid expertise[2], to deliver Tizanidine, a centrally acting muscle relaxant. MEDRx has concluded Phase I trials in U.S. with a promising horizon for further clinical development. Annual sales of muscle relaxants in the United States were estimated at ~$807 million[3] in 2016. MRX-4TZT is expected to be the first transdermal muscle relaxant worldwide. Delivering Tizanidine by transdermal administration, rather than by oral administration, is expected to improve patient experience on the drug by providing sustained efficacy while also reducing adverse events and side effects such as aesthenia, troublesome drowsiness and dry mouth amongst others. Cipla plans to initiate Phase 3 clinical trials after completion of additional Phase 1 studies.

After bolstering its US generics business through two acquisitions last year, Cipla is now actively foraying into the US branded specialty space through a blend of in-house innovation and inorganic efforts. Umang Vohra, MD and Global CEO Cipla Ltd., said: "In-line with our legacy and philosophy of keeping the patient at the centre, we believe that the Tizanidine transdermal patch will address significant unmet needs and benefit patients globally suffering from chronic Spasticity."

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

About Cipla USA Inc.

Through a comprehensive partnership model approach, Cipla has been dedicated to providing access to medicines at an affordable price for over 30 years in the US. Cipla USA own label was launched in January 2015. Cipla has executed over 20 US partnerships and currently has commercialized products in the US. The Company has supported the development of more than 170 ANDAs. Cipla USA brings a variety of technologies to the US markets in order to keep its ongoing commitment to provide access to high quality complex products at affordable prices.

<Reference>

1 Tizanidine

Tizanidine is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve muscle tonicity). This drug is used to alleviate discomfort from shoulder stiffness, back problems, frozen shoulder, tension headaches and other problems.

2 Ionic liquid

An ionic liquid is a salt with a melting point of not more than 100ºC and is also called a room temperature molten salt. Properties include a low melting point, high ion conductivity, high polarity, non-volatility and non-combustibility. Many applications are being examined for ionic liquids, including in solar cells and environmentally responsible reaction solvents. MEDRx was first in the world to discover that converting drugs into ionic liquids and dissolving drugs in ionic liquids can dramatically increase the transdermal permeability of these drugs. MEDRx has gained considerable knowledge involving ionic liquids. There is a library of ionic liquids that are believed to be safe by combining them with compounds that have already been used for human consumption. MEDRx has expertise in selecting ionic liquids that are best suited to increasing the transdermal permeability of targeted drugs. And MEDRx has the know-how to produce drugs in format that is easy to use (patches, ointments, etc.) while retaining the properties of ionic liquids that contain drugs. The exclusive technology for producing transdermal drugs, which incorporates this knowledge, is called the Ionic Liquid Transdermal System (ILTS®).

3 Estimates: Cipla IMS 2016 data.

Media Contacts:
Corporate Communications
Pallavi Golar
E Mail: pallavi.golar@cipla.com

Investor Relations
Alpesh Dalal
E-Mail: Investor.Relations@cipla.com